|
1
|
European Network of Cancer Registries
(ENCR): Eurocim. Version 4.0. European incidence database v2.3, 730
entity dictionary. Lyon: ENCR. 2001.
|
|
2
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Katz DL, Zheng T, Holford TR and Flannery
J: Time trends in the incidence of renal carcinoma: Analysis of
connecticut tumor registry data, 1935–1989. Int J Cancer. 58:57–63.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fisher R, Gore M and Larkin J: Current and
future systemic treatments for renal cell carcinoma. Semin Cancer
Biol. 23:38–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kroeger N, Choueiri TK, Lee J-L, Bjarnason
GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha
SY, et al: Survival outcome and treatment response of patients with
late relapse from renal cell carcinoma in the era of targeted
therapy. Eur Urol. 65:1086–1092. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Keegan KA, Schupp CW, Chamie K, Hellenthal
NJ, Evans CP and Koppie TM: Histopathology of surgically treated
renal cell carcinoma: Survival differences by subtype and stage. J
Urol. 188:391–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Franklin JR, Figlin R, Rauch J, Gitlitz B
and Belldegrun A: Cytoreductive surgery in the management of
metastatic renal cell carcinoma: The UCLA experience. Semin Urol
Oncol. 14:230–236. 1996.PubMed/NCBI
|
|
8
|
Sarna G, Figlin R and de Kernion J:
Interferon in renal cell carcinoma. The UCLA experience. Cancer.
59(Suppl 3): 610–612. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili
R, Bjarnason GA, et al: Overall survival and updated results for
sunitinib compared with interferon alfa in patients with metastatic
renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Motzer RJ, Hutson TE, Cella D, Reeves J,
Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et
al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Motzer RJ, Escudier B, Tomczak P, Hutson
TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J,
Hariharan S, et al: Axitinib versus sorafenib as second-line
treatment for advanced renal cell carcinoma: Overall survival
analysis and updated results from a randomised phase 3 trial.
Lancet Oncol. 14:552–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: TARGET Study Group: Sorafenib in advanced clear-cell
renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sternberg CN, Davis ID, Mardiak J,
Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA,
Kavina A, et al: Pazopanib in locally advanced or metastatic renal
cell carcinoma: Results of a randomized phase III trial. J Clin
Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Motzer RJ, Escudier B, Oudard S, Hutson
TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA,
Hollaender N, et al: RECORD-1 Study Group: Efficacy of everolimus
in advanced renal cell carcinoma: A double-blind, randomised,
placebo-controlled phase III trial. Lancet. 372:449–456. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ljungberg B (chair), Bensalah K, Bex A
(vice-chair), Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk
MA, Lam T, Marconi L, et al: Guidelines on Renal Cell Carcinoma.
European Association of Urology. 2015.
|
|
17
|
Hutson TE, Escudier B, Esteban E,
Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR,
Hariharan S, et al: Randomized phase III trial of temsirolimus
versus sorafenib as second-line therapy after sunitinib in patients
with metastatic renal cell carcinoma. J Clin Oncol. 32:760–767.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Motzer RJ, Barrios CH, Kim TM, Falcon S,
Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha
SY, et al: Phase II randomized trial comparing sequential
first-line everolimus and second-line sunitinib versus first-line
sunitinib and second-line everolimus in patients with metastatic
renal cell carcinoma. J Clin Oncol. 32:2765–2772. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Escudier B, Porta C, Schmidinger M, Algaba
F, Patard JJ, Khoo V, Eisen T and Horwich A: ESMO Guidelines
Working Group: Renal cell carcinoma: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
25(Suppl 3): iii49–iii56. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: CheckMate 025 Investigators: Nivolumab versus
everolimus in advanced renal-cell carcinoma. N Engl J Med.
373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Choueiri TK, Escudier B, Powles T,
Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee J-L,
Peltola K, et al: METEOR Investigators: Cabozantinib versus
everolimus in advanced renal-cell carcinoma. N Engl J Med.
373:1814–1823. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hamid O and Carvajal RD: Anti-programmed
death-1 and anti-programmed death-ligand 1 antibodies in cancer
therapy. Expert Opin Biol Ther. 13:847–861. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hamanishi J, Mandai M, Iwasaki M, Okazaki
T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N,
et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+
T lymphocytes are prognostic factors of human ovarian cancer. Proc
Natl Acad Sci USA. 104:3360–3365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Motzer RJ, Bacik J, Schwartz LH, Reuter V,
Russo P, Marion S and Mazumdar M: Prognostic factors for survival
in previously treated patients with metastatic renal cell
carcinoma. J Clin Oncol. 22:454–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cella D, Yount S, Brucker PS, Du H,
Bukowski R, Vogelzang N and Bro WP: Development and validation of a
scale to measure disease-related symptoms of kidney cancer. Value
Health. 10:285–293. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Motzer RJ, Sharma P, McDermott DF, George
S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: CheckMate 025 phase iII trial: Outcomes by key
baseline factors and prior therapy for nivolumab (nIVO) versus
everolimus (eVE) in advanced renal cell carcinoma (rCC). J Clin
Oncol. 34(Suppl 2S): Abstr 498. 2016.
|
|
27
|
Thompson RH, Gillett MD, Cheville JC,
Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen
L, et al: Costimulatory B7-H1 in renal cell carcinoma patients:
Indicator of tumor aggressiveness and potential therapeutic target.
Proc Natl Acad Sci USA. 101:17174–17179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Omori S, Kenmotsu H, Abe M, Watanabe R,
Sugino T, Wakuda K, Ono A, Taira T, Naito T, Murakami H, et al:
Changes in pD-l1 expression in non-small cell lung cancer by
immunohistochemical analysis. J Clin Oncol. 33:Abstr e22118.
2015.
|
|
29
|
Gibney GT, Aziz SA, Camp RL, Conrad P,
Schwartz BE, Chen CR, Kelly WK and Kluger HM: c-Met is a prognostic
marker and potential therapeutic target in clear cell renal cell
carcinoma. Ann Oncol. 24:343–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rankin EB, Fuh KC, Castellini L,
Viswanathan K, Finger EC, Diep AN, LaGory EL, Kariolis MS, Chan A,
Lindgren D, et al: Direct regulation of GAS6/AXL signaling by HIF
promotes renal metastasis through SRC and MET. Proc Natl Acad Sci
USA. 111:13373–13378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Viola D, Cappagli V and Elisei R:
Cabozantinib (XL184) for the treatment of locally advanced or
metastatic progressive medullary thyroid cancer. Future Oncol.
9:1083–1092. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Armstrong AJ, Broderick S, Eisen T,
Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins
RE, Hainsworth JD, et al: Final clinical results of a randomized
phase II international trial of everolimus vs. sunitinib in
patients with metastatic non-clear cell renal cell carcinoma
(ASPEN). J Clin Oncol. 33:Abstr 4507. 2015.
|
|
33
|
Heng DY, Mackenzie MJ, Vaishampayan UN,
Bjarnason GA, Knox JJ, Tan MH, Wood L, Wang Y, Kollmannsberger C,
North S, et al: Primary anti-vascular endothelial growth factor
(VEGF)-refractory metastatic renal cell carcinoma: Clinical
characteristics, risk factors, and subsequent therapy. Ann Oncol.
23:1549–1555. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hales RK, Banchereau J, Ribas A, Tarhini
AA, Weber JS, Fox BA and Drake CG: Assessing oncologic benefit in
clinical trials of immunotherapy agents. Ann Oncol. 21:1944–1951.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wolchok JD, Hoos A, O'Day S, Weber JS,
Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al:
Guidelines for the evaluation of immune therapy activity in solid
tumors: Immune-related response criteria. Clin Cancer Res.
15:7412–7420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Scher HI, Halabi S, Tannock I, Morris M,
Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ,
Dreicer R, et al: Prostate Cancer Clinical Trials Working Group:
Design and end points of clinical trials for patients with
progressive prostate cancer and castrate levels of testosterone:
Recommendations of the Prostate Cancer Clinical Trials Working
Group. J Clin Oncol. 26:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Corsello SM, Barnabei A, Marchetti P, De
Vecchis L, Salvatori R and Torino F: Endocrine side effects induced
by immune checkpoint inhibitors. J Clin Endocrinol Metab.
98:1361–1375. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Motzer RJ, Rini BI, McDermott DF, Redman
BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S,
Logan TF, et al: Nivolumab for metastatic renal cell carcinoma:
Results of a randomized phase iI trial. J Clin Oncol. 33:1430–1437.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Eichelberg C, Vervenne WL, De Santis M, et
al: SWITCH: A randomised, sequential, open-label study to evaluate
the efficacy and safety of sorafenib-sunitinib versus
sunitinib-sorafenib in the treatment of metastatic renal cell
cancer. Eur Urol. 68:837–847. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Motzer RJ, Escudier B, Oudard S, Hutson
TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA,
Hollaender N, et al: RECORD-1 study group: Phase 3 trial of
everolimus for metastatic renal cell carcinoma: Final results and
analysis of prognostic factors. Cancer. 116:4256–4265. 2010.
View Article : Google Scholar : PubMed/NCBI
|
